Cabaletta Bio (CABA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Jun, 2026Executive summary
Annual Meeting scheduled for June 9, 2026, with participation via live webcast.
Supplement updates the original proxy statement filed on April 28, 2026.
Record date for voting eligibility is April 20, 2026.
Voting matters and shareholder proposals
Proposal 3, regarding an amendment to the 2019 Stock Option and Incentive Plan, has been withdrawn and will not be considered.
All other proposals (1, 2, 4, 5, and 6) remain on the agenda and will be voted as directed.
Proxy cards or instructions for Proposal 3 will not be counted; no need to resubmit proxies unless changing votes on remaining proposals.
Board of directors and corporate governance
Board decided to withdraw Proposal 3 after discussions with management and advisors.
Board reserves the right to propose future amendments to the equity compensation plan.
Latest events from Cabaletta Bio
- Q2 2026 net loss was $51M; strong cash reserves support late-stage autoimmune clinical programs.CABA
Q2 2026 - Rese-cel delivers durable, safe immune reset in autoimmunity, enabled by scalable, automated manufacturing.CABA
Corporate presentation - Rese-cel delivers durable, safe remissions in myositis, supporting rapid outpatient adoption.CABA
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Durable, safe cell therapy shows promise for autoimmune diseases, enabling outpatient access.CABA
Jefferies Global Healthcare Conference 2026 - Rese-cel demonstrates robust efficacy and safety, enabling scalable outpatient therapy for autoimmunity.CABA
Corporate presentation - Automated CAR T manufacturing and preconditioning-free regimens drive scalable autoimmune therapy.CABA
H.C. Wainwright 4th Annual BioConnect Investor Conference - Rese-cel delivers durable, safe, and scalable CAR T therapy for autoimmune diseases.CABA
Corporate presentation - Q1 2026 net loss was $43.5M; $141M and $150M financings extend runway into mid-2027.CABA
Q1 2026 - CABA-201 shows promising safety and efficacy, supporting drug-free remission in autoimmune diseases.CABA
Status Update